Immunome, Inc. (NASDAQ: IMNM) is scheduled to announce its earnings for the fourth quarter of 2025 on March 18, 2026, before market opening. Analysts anticipate that the biotechnology firm will report a loss of ($0.64) per share, with projected revenues of $0.785 million for the quarter. Investors can access the earnings summary page for the latest updates on the earnings call set for March 3, 2026, at 15:00 ET.
In its previous earnings report on March 3, 2025, Immunome recorded an earnings per share (EPS) of ($0.75), falling short of the consensus estimate of ($0.65) by ($0.10). The company’s financial health is reflected in a negative return on equity of 57.61% and a staggering negative net margin of 1,687.08%. Looking ahead, analysts forecast an average EPS of ($2) for the current fiscal year and ($3) for the next.
Market Performance and Institutional Activity
On March 15, 2026, shares of Immunome opened at $20.36, representing a decline of 3.0%. The company currently boasts a market capitalization of $2.30 billion, with a price-to-earnings ratio of -8.41 and a beta of 2.12. The stock has fluctuated significantly over the past year, with a low of $5.15 and a high of $27.65.
Recent activity among institutional investors highlights shifting confidence in Immunome. T. Rowe Price Investment Management Inc. increased its holdings by 59.4% in the fourth quarter, acquiring an additional 5,003,824 shares, bringing its total to 13,421,987 shares valued at $288.3 million. Invesco Ltd. raised its stake by an impressive 382.1%, now holding 270,065 shares worth $5.8 million. Other firms, including Virtus Investment Advisers LLC and Wellington Management Group LLP, have also increased their investments, reflecting a broader institutional interest in the company.
Analysts Update Price Targets
Equity analysts have recently revised their price targets for Immunome’s stock. Evercore upgraded its forecast from $18.00 to $40.00, assigning an “outperform” rating. Conversely, Wall Street Zen downgraded the stock from a “hold” to a “sell” rating. Lake Street Capital also raised its target from $22.00 to $32.00, maintaining a “buy” rating. Notably, Craig Hallum increased its target from $33.00 to $36.00, affirming a “buy” rating.
Overall, ten analysts currently rate Immunome as a “buy,” while one has assigned a “sell” rating. According to MarketBeat, the stock has an average rating of “Moderate Buy” with a target price of $33.45.
Immunome, Inc. operates as a clinical-stage biotechnology company, focusing on the discovery and development of novel antibody-based therapeutics aimed at treating oncology and infectious diseases. The firm employs a proprietary platform to identify fully human monoclonal antibodies, utilizing the B-cell repertoire from patients with active disease. Its prominent program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
Investors and analysts alike will be closely monitoring the upcoming earnings report for insights into Immunome’s financial trajectory and strategic direction.
